从肿瘤生物学进展探讨复发难治滤泡性淋巴瘤的识别和治疗

The identification and treatment options for patients with relapsed and refractory follicular lymphoma from the perspective of advancements in tumor biology

滤泡性淋巴瘤(FL)是B细胞恶性肿瘤的常见亚型,具有高度异质性。尽管大多数FL患者诊断时临床表现为惰性,但早期进展或复发,多次复发,或转化为高级别淋巴瘤的患者,死亡风险高,预后差。然而,目前广泛使用的预后模型未能很好地识别这一群体;多次复发的患者耗尽现有治疗方案后,面临无药可治。FL在肿瘤生物学方面的深入研究,为复发难治FL患者提供了新的识别策略、治疗依据和治疗方案。本文就FL的肿瘤生物学的进展,评述复发难治FL患者的识别和治疗选择。

Follicular lymphoma(FL)is a common subtype of B-cell malignancy,highly heterogeneous.While the majority of FL patients are clinically indolent at diagnosis,those who experience early progression or recurrence,multiple recurrences,or transformation into high-grade lymphoma are at a higher risk of mortality.However,prognostic models currently in widespread use are inadequate at accurately identifying the population;patients experiencing multiple recurrences are left without a remedy after exhaustion of existing treatment options.The development of tumor biology in FL has provided novel approaches for identifying strategies,establishing treatment foundations,and expanding treatment alternatives for patients with relapsed and refractory FL(R/R FL).This article provides an overview of the advancements in tumor biology related to FL and explores the identification and treatment options for R/R FL.